ESR1 and breast carcinoma: Here, to demonstrate the utility of “integrative HLA typing”, we applied our strategy on two independent datasets where primary breast cancer and matched adjacent normal breast tissue were available (consisting of triple-negative breast cancer (TNBC) and estrogen receptor-positive (ER +)/HER2-negative (HER2-) tumors).